Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $3.58 Analyst target: $10.75 Upside: 200.28%
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of drugs to treat central nervous system (CNS) diseases and other disorders in the United States. The company is headquartered in New York, New York.
See the full interactive analysis & chart →Informational only — not investment advice.